A Placebo-controlled, Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs ASP 8302 (Primary)
- Indications Bladder dysfunction
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 16 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.